UroGen Pharma ($URGN) Reports Strong Revenue Growth and Narrowed Losses in Q3 Total revenue reached $89.0 million, up sharply from $27.5 million a year earlier

UroGen Pharma ($URGN) Reports Strong Revenue Growth and Narrowed Losses in Q3 Total revenue reached $89.0 million, up sharply from $27.5 million a year earlier, though it came in slightly below consensus estimates of about $90.6 million. The net loss narrowed dramatically to $1.5 million, or $0.03…